We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

31 hedge funds and large institutions have $3.77M invested in Lisata Therapeutics in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more capital invested

Capital invested by funds: $1.59M → $3.77M (+$2.18M)

29% more funds holding

Funds holding: 24 → 31 (+7)

0.14% more ownership

Funds ownership: 0.38% → 0.52% (+0.14%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
31
Holders Change
+7
Holders Change %
+29.17%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$394K
2
Renaissance Technologies
Renaissance Technologies
New York
+$187K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$156K
4
Ameriprise
Ameriprise
Minnesota
+$131K
5
JP Morgan Chase
JP Morgan Chase
New York
+$86.6K

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$180K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$6.03K
3
BlackRock
BlackRock
New York
-$1.59K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$69
5
UBS Group
UBS Group
Switzerland
-$69
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.09M +$394K +5,693 +84%
Renaissance Technologies
2
Renaissance Technologies
New York
$859K +$187K +2,706 +38%
BlackRock
3
BlackRock
New York
$274K -$1.59K -23 -0.7%
Macquarie Group
4
Macquarie Group
Australia
$233K +$46K +664 +33%
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$212K -$6.03K -87 -3%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$197K +$156K +2,251 New
Ameriprise
7
Ameriprise
Minnesota
$175K +$131K +1,898 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$157K – – –
PAM
9
Panagora Asset Management
Massachusetts
$123K -$180K -2,599 -65%
JP Morgan Chase
10
JP Morgan Chase
New York
$110K +$86.6K +1,251 New
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$79K +$62.3K +900 New
STA
12
Summit Trail Advisors
New York
$73K – – –
Millennium Management
13
Millennium Management
New York
$62K +$49K +708 New
Creative Planning
14
Creative Planning
Kansas
$59K +$208 +3 +0.4%
Bank of America
15
Bank of America
North Carolina
$14K – – –
RFC
16
Regions Financial Corp
Alabama
$13K – – –
UBS Group
17
UBS Group
Switzerland
$9K -$69 -1 -1%
Fifth Third Bancorp
18
Fifth Third Bancorp
Ohio
$6K – – –
LTFS
19
Ladenburg Thalmann Financial Services
Florida
$6K – – –
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$5K -$69 -1 -2%
IA
21
IFP Advisors
Florida
$2K – – –
Northwestern Mutual Wealth Management
22
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
Citigroup
23
Citigroup
New York
$1K – – –
WOC
24
West Oak Capital
California
$584 +$485 +7 New
RE
25
RBC Europe
United Kingdom
$58 – – –
1
2

LSTA Hedge Fund Activity: Q1 2018 in Review

31 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2018, worth a combined $3.77M — up 137% from $1.59M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LSTA positions and 0 closed out — a net gain of 7 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $394K. The largest seller was Panagora Asset Management, cutting an estimated $180K.

  • 31 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2018, up from 24 in Q4 2017.
  • Funds reported $3.77M of Lisata Therapeutics stock for Q1 2018, up 137% quarter-over-quarter.
  • 7 funds opened new Lisata Therapeutics positions in Q1 2018 and 0 closed out, a net change of +7 holders.
  • The largest Lisata Therapeutics buyer in Q1 2018 was Vanguard Group, an estimated $394K added.
  • The largest Lisata Therapeutics seller in Q1 2018 was Panagora Asset Management, an estimated $180K sold.

Based on aggregated 13F filings for Q1 2018.